DCF Advisers LLC Takes Position in Zenas BioPharma, Inc. $ZBIO

DCF Advisers LLC acquired a new position in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 28,184 shares of the company’s stock, valued at approximately $715,000.

Several other hedge funds have also modified their holdings of ZBIO. SR One Capital Management LP increased its position in Zenas BioPharma by 2.6% during the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after purchasing an additional 126,315 shares during the last quarter. NEA Management Company LLC boosted its holdings in shares of Zenas BioPharma by 28.9% in the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after purchasing an additional 789,500 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of Zenas BioPharma by 45.9% in the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after purchasing an additional 853,740 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Zenas BioPharma during the 2nd quarter valued at $68,176,000. Finally, Vanguard Group Inc. grew its stake in shares of Zenas BioPharma by 25.0% during the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after buying an additional 290,307 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ZBIO. Zacks Research raised Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Wall Street Zen raised Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Guggenheim restated a “buy” rating and set a $55.00 price target on shares of Zenas BioPharma in a research note on Friday, August 14th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research note on Friday, August 14th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $45.71.

Zenas BioPharma Stock Performance

Zenas BioPharma stock opened at $31.25 on Thursday. The stock’s 50 day moving average price is $27.74 and its 200 day moving average price is $23.63. The firm has a market capitalization of $2.04 billion, a PE ratio of -3.48 and a beta of -1.03. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93. Zenas BioPharma, Inc. has a one year low of $13.50 and a one year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The business had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $15.00 million. As a group, sell-side analysts expect that Zenas BioPharma, Inc. will post -5.81 EPS for the current fiscal year.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.